Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study.
Blondeaux E, Lambertini M, Michelotti A, Conte B, Benasso M, Dellepiane C, Bighin C, Pastorino S, Levaggi A, Alonzo A, Poggio F, Buzzatti G, Molinelli C, Fregatti P, Bertoglio S, Boccardo F, Del Mastro L. Blondeaux E, et al. Among authors: fregatti p. Br J Cancer. 2020 May;122(11):1611-1617. doi: 10.1038/s41416-020-0816-8. Epub 2020 Mar 31. Br J Cancer. 2020. PMID: 32231293 Free PMC article. Clinical Trial.
Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.
Cirmena G, Garuti A, De Mariano M, Coco S, Ferrando L, Isnaldi E, Barbero V, Fregatti P, Del Mastro L, Ferrando F, Gonella R, Garlaschi A, Friedman D, Ballestrero A, Zoppoli G. Cirmena G, et al. Among authors: fregatti p. J Oncol. 2020 Jan 22;2020:8132507. doi: 10.1155/2020/8132507. eCollection 2020. J Oncol. 2020. PMID: 32377196 Free PMC article.
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.
Conte B, Bruzzone M, Lambertini M, Poggio F, Bighin C, Blondeaux E, De Laurentiis M, Valle E, Cognetti F, Nisticò C, De Placido S, Garrone O, Gamucci T, Montemurro F, Puglisi F, Cardinali B, Fregatti P, Miglietta L, Boccardo F, Ceppi M, Del Mastro L; GIM2 Investigators. Conte B, et al. Among authors: fregatti p. Eur J Cancer. 2020 Sep;136:43-51. doi: 10.1016/j.ejca.2020.05.007. Epub 2020 Jul 4. Eur J Cancer. 2020. PMID: 32634760 Clinical Trial.
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study.
Blondeaux E, Ferreira AR, Poggio F, Puglisi F, Bighin C, Sottotetti F, Montemurro F, Poletto E, Lai A, Sini V, Minuti G, Mura S, Fontana A, Fregatti P, Cardinali B, Lambertini M, Del Mastro L. Blondeaux E, et al. Among authors: fregatti p. ESMO Open. 2020 Aug;5(4):e000719. doi: 10.1136/esmoopen-2020-000719. ESMO Open. 2020. PMID: 32817059 Free PMC article.
Update on the Management of Breast Cancer during Pregnancy.
Poggio F, Tagliamento M, Pirrone C, Soldato D, Conte B, Molinelli C, Cosso M, Fregatti P, Del Mastro L, Lambertini M. Poggio F, et al. Among authors: fregatti p. Cancers (Basel). 2020 Dec 3;12(12):3616. doi: 10.3390/cancers12123616. Cancers (Basel). 2020. PMID: 33287242 Free PMC article. Review.
67 results